Payment overview · 2025
General Payments
$844.54
31 reported records · 12 companies
Healthcare provider profile · identity verified
Yong Tan, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BRAWLEY, CA · NPI 1083771489
Verified facts
What the public records show
CMS Open Payments records show Yong Tan, M.D. received $844.54 in general payments during 2025 across 31 reported records.
Novo Nordisk Inc accounted for 31.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $268.12 | 31.8% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $170.01 | 20.1% | 5 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $84.08 | 10.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $60.59 | 7.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.96 | 6.2% | 3 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $43.39 | 5.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.79 | 4.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.35 | 3.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.87 | 3.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $25.38 | 3.0% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $22.28 | 2.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.72 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $844.54 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $154.80 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $111.25 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $96.04 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $84.08 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $51.96 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.96 | 3 | 2025 |
Source payment records
|
|||||
| PANGEA Normalized: pangea |
Device | Stryker Corporation | $43.39 | 1 | 2025 |
Source payment records
|
|||||
| PROSTEP MICA Normalized: prostep mica |
Device | Stryker Corporation | $43.39 | 1 | 2025 |
Source payment records
|
|||||
| VIAFLOW Normalized: viaflow |
Device | Stryker Corporation | $43.39 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.79 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $37.79 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $33.33 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.35 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $29.87 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $27.26 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $25.38 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Cardiac Ambulatory Monitor Normalized: hillrom cardiac ambulatory monitor |
Device | Baxter Healthcare | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 118 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 95 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 78 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 40 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
78 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
118 | 41 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
110 | 15 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
110 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 799 | 272 |
| Amlodipine Besylate | Amlodipine Besylate | 477 | 162 |
| Losartan Potassium | Losartan Potassium | 436 | 134 |
| Levothyroxine Sodium | Levothyroxine Sodium | 427 | 122 |
| Metformin Hcl | Metformin Hcl | 407 | 137 |
| Lisinopril | Lisinopril | 356 | 121 |
| Gabapentin | Gabapentin | 328 | 130 |
| Simvastatin | Simvastatin | 256 | 86 |
| Omeprazole | Omeprazole | 253 | 99 |
| Escitalopram Oxalate | Escitalopram Oxalate | 228 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 215 | 78 |
| Furosemide | Furosemide | 176 | 69 |
| Alendronate Sodium | Alendronate Sodium | 170 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 135 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 48 |
| Carvedilol | Carvedilol | 118 | 41 |
| Farxiga | Dapagliflozin Propanediol | 118 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 40 |
| Azithromycin | Azithromycin | 116 | 100 |
| Trazodone Hcl | Trazodone Hcl | 115 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 114 | 42 |
| Ibuprofen | Ibuprofen | 112 | 55 |
| Ozempic | Semaglutide | 110 | 20 |
| Trulicity | Dulaglutide | 110 | 15 |
| Glimepiride | Glimepiride | 105 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 46 |
| Jardiance | Empagliflozin | 95 | 27 |
| Glipizide | Glipizide | 91 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 90 | 31 |
| Meloxicam | Meloxicam | 90 | 30 |
| Eliquis | Apixaban | 87 | 24 |
| Potassium Chloride | Potassium Chloride | 87 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 28 |
| Linzess | Linaclotide | 78 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 34 |
| Sertraline Hcl | Sertraline Hcl | 74 | 24 |
| Montelukast Sodium | Montelukast Sodium | 73 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 69 | 20 |
| Allopurinol | Allopurinol | 67 | 23 |
| Icosapent Ethyl | Icosapent Ethyl | 64 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 58 | 47 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 19 |
| Tramadol Hcl | Tramadol Hcl | 56 | 16 |
| Cephalexin | Cephalexin | 55 | 48 |
| Tresiba Flextouch U-200 | Insulin Degludec | 55 | 14 |
| Entresto | Sacubitril/Valsartan | 54 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 21 |
| Januvia | Sitagliptin Phosphate | 54 | 17 |
| Vascepa | Icosapent Ethyl | 53 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 52 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | 18 |
| Lorazepam | Lorazepam | 48 | 19 |
| Tradjenta | Linagliptin | 47 | 13 |
| Ezetimibe | Ezetimibe | 45 | 17 |
| Famotidine | Famotidine | 45 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 21 |
| Mounjaro | Tirzepatide | 40 | 11 |
| Valsartan | Valsartan | 39 | 15 |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Baclofen | Baclofen | 37 | 12 |
| Celecoxib | Celecoxib | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Alprazolam | Alprazolam | 35 | 14 |
| Benazepril Hcl | Benazepril Hcl | 35 | 11 |
| Memantine Hcl | Memantine Hcl | 35 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 21 |
| Meclizine Hcl | Meclizine Hcl | 34 | 23 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | 13 |
| Prednisone | Prednisone | 32 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 30 | suppressed |
| Irbesartan | Irbesartan | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | 13 |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 27 | suppressed |
| Finasteride | Finasteride | 27 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 21 |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | 12 |
| Lidocaine | Lidocaine | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Procto-Med Hc | Hydrocortisone | 23 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | 11 |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | 12 |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 14 |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $844.54 · 31 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, FARXIGA, Hillrom - Cardiac Ambulatory Monitor, JARDIANCE, Korlym, LEQVIO, LINZESS, MOUNJARO, OTEZLA, PANGEA, PROSTEP MICA, REPATHA, SHINGRIX, Senza, TRELEGY ELLIPTA, VIAFLOW, Wegovy, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error